CTSF
Basic information
Region (hg38): 11:66563464-66568879
Links
Phenotypes
GenCC
Source:
- neuronal ceroid lipofuscinosis 13 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Supportive), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Strong), mode of inheritance: AR
- neuronal ceroid lipofuscinosis 13 (Limited), mode of inheritance: Unknown
- neuronal ceroid lipofuscinosis 13 (Definitive), mode of inheritance: AR
- adult neuronal ceroid lipofuscinosis (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Neuronal ceroid lipofuscinosis 13 | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Biochemical; Neurologic | 20301601; 23297359 |
ClinVar
This is a list of variants' phenotypes submitted to
- Inborn_genetic_diseases (113 variants)
- Neuronal_ceroid_lipofuscinosis_13 (111 variants)
- not_provided (98 variants)
- CTSF-related_disorder (14 variants)
- not_specified (11 variants)
- Neuronal_ceroid_lipofuscinosis (9 variants)
- Neurodevelopmental_disorder (2 variants)
- See_cases (1 variants)
- Developmental_disorder (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CTSF gene is commonly pathogenic or not. These statistics are base on transcript: NM_000003793.4. Only rare variants are included in the table.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Effect | PathogenicP | Likely pathogenicLP | VUSVUS | Likely benignLB | BenignB | Sum |
---|---|---|---|---|---|---|
synonymous | 37 | 38 | ||||
missense | 113 | 14 | 136 | |||
nonsense | 10 | |||||
start loss | 0 | |||||
frameshift | 10 | 18 | ||||
splice donor/acceptor (+/-2bp) | 8 | |||||
Total | 14 | 25 | 117 | 51 | 3 |
Highest pathogenic variant AF is 0.0000706384
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CTSF | protein_coding | protein_coding | ENST00000310325 | 13 | 5379 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.94e-13 | 0.112 | 125693 | 0 | 55 | 125748 | 0.000219 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.744 | 217 | 250 | 0.868 | 0.0000145 | 3086 |
Missense in Polyphen | 88 | 113.43 | 0.7758 | 1329 | ||
Synonymous | -0.246 | 105 | 102 | 1.03 | 0.00000625 | 959 |
Loss of Function | 0.753 | 22 | 26.2 | 0.841 | 0.00000121 | 304 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000518 | 0.000518 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000875 | 0.000870 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.000132 | 0.000132 |
Middle Eastern | 0.000875 | 0.000870 |
South Asian | 0.000393 | 0.000392 |
Other | 0.000163 | 0.000163 |
dbNSFP
Source:
- Function
- FUNCTION: Thiol protease which is believed to participate in intracellular degradation and turnover of proteins. Has also been implicated in tumor invasion and metastasis.;
- Pathway
- Lysosome - Homo sapiens (human);Apoptosis - Homo sapiens (human);MHC class II antigen presentation;Immune System;Adaptive Immune System
(Consensus)
Recessive Scores
- pRec
- 0.152
Intolerance Scores
- loftool
- 0.466
- rvis_EVS
- 0.49
- rvis_percentile_EVS
- 79.46
Haploinsufficiency Scores
- pHI
- 0.133
- hipred
- N
- hipred_score
- 0.123
- ghis
- 0.441
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- S
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.199
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Ctsf
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype;
Gene ontology
- Biological process
- proteolysis;antigen processing and presentation of exogenous peptide antigen via MHC class II;proteolysis involved in cellular protein catabolic process
- Cellular component
- extracellular space;lysosome;lysosomal lumen;extracellular exosome;extracellular vesicle
- Molecular function
- cysteine-type endopeptidase activity